BioMimetic Therapeutics, Inc. Closes Enrollment With 436 Patients In North American Pivotal Study For Augment? Bone Graft

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced that as of December 31, 2008, 436 patients were enrolled in the Company’s North American pivotal clinical study for its lead orthopedic product candidate Augment? Bone Graft. Enrollment is now closed in this study to assess the safety and efficacy of Augment for the treatment of foot and ankle fusions as compared to autograft, the current gold standard for bone grafting in this type of surgery.

More: continued here

Filed under: Bones on January 14th, 2009